Trials / Recruiting
RecruitingNCT07315113
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
A Phase 1b Clinical Study of NXP900 in Combination With Osimertinib in Subjects With Advanced, EGFRMut+ Non-Small Cell Lung Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Nuvectis Pharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NXP900 | NXP900 is an orally administered inhibitor of SRC family kinases (SFK) |
| DRUG | Osimertinib | Osimertinib is an orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor |
Timeline
- Start date
- 2025-12-18
- Primary completion
- 2026-12-01
- Completion
- 2027-06-01
- First posted
- 2026-01-02
- Last updated
- 2026-01-02
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07315113. Inclusion in this directory is not an endorsement.